201 related articles for article (PubMed ID: 22826745)
1. Estimating the cost to rural ambulating HIV/AIDS patients on highly active antiretroviral therapy (HAART) in rural Ghana: a pilot study.
Apanga S; Punguyire D; Adjei G
Pan Afr Med J; 2012; 12():21. PubMed ID: 22826745
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of highly active antiretroviral therapy in South Africa.
Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ
PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413
[TBL] [Abstract][Full Text] [Related]
3. Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.
Ghatnekar O; Hjortsberg C; Gisslén M; Lindbäck S; Löthgren M
Pharmacoeconomics; 2010; 28 Suppl 1():49-57. PubMed ID: 21182343
[TBL] [Abstract][Full Text] [Related]
4. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.
Krentz HB; Auld MC; Gill MJ;
CMAJ; 2003 Jul; 169(2):106-10. PubMed ID: 12874156
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
[TBL] [Abstract][Full Text] [Related]
6. Expenditures for the care of HIV-infected patients in rural areas in China's antiretroviral therapy programs.
Zhou F; Kominski GF; Qian HZ; Wang J; Duan S; Guo Z; Zhao X
BMC Med; 2011 Jan; 9():6. PubMed ID: 21241494
[TBL] [Abstract][Full Text] [Related]
7. The direct costs of HIV/AIDS care.
Levy AR; James D; Johnston KM; Hogg RS; Harrigan PR; Harrigan BP; Sobolev B; Montaner JS
Lancet Infect Dis; 2006 Mar; 6(3):171-7. PubMed ID: 16500598
[TBL] [Abstract][Full Text] [Related]
8. Financial burden of health care for HIV/AIDS patients in Vietnam.
Tran BX; Duong AT; Nguyen LT; Hwang J; Nguyen BT; Nguyen QT; Nong VM; Vu PX; Ohinmaa A
Trop Med Int Health; 2013 Feb; 18(2):212-8. PubMed ID: 23210600
[TBL] [Abstract][Full Text] [Related]
9. Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting.
Torti C; Casari S; Palvarini L; Quiros-Roldan E; Moretti F; Leone L; Patroni A; Castelli F; Ripamonti D; Tramarin A; Carosi G
Health Policy; 2003 Sep; 65(3):261-7. PubMed ID: 12941493
[TBL] [Abstract][Full Text] [Related]
10. The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life.
Hubben GA; Bishai D; Pechlivanoglou P; Cattelan AM; Grisetti R; Facchin C; Compostella FA; Bos JM; Postma MJ; Tramarin A
AIDS Care; 2008 Apr; 20(4):449-55. PubMed ID: 18449822
[TBL] [Abstract][Full Text] [Related]
11. Brief communication: economic comparison of opportunistic infection management with antiretroviral treatment in people living with HIV/AIDS presenting at an NGO clinic in Bangalore, India.
John KR; Rajagopalan N; Madhuri KV
MedGenMed; 2006 Nov; 8(4):24. PubMed ID: 17415293
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of highly active antiretroviral therapy for HIV infection in Taiwan.
Fang CT; Chang YY; Hsu HM; Twu SJ; Chen KT; Chen MY; Huang LY; Hwang JS; Wang JD
J Formos Med Assoc; 2007 Aug; 106(8):631-40. PubMed ID: 17711796
[TBL] [Abstract][Full Text] [Related]
14. Pediatric HIV costs across three treatment eras from 1986 to 2007.
Wilson LS; Basu R; Christenson M; Hensic L; Paoli C; Wara D; Moskowitz JT
Pediatrics; 2010 Sep; 126(3):e541-9. PubMed ID: 20696721
[TBL] [Abstract][Full Text] [Related]
15. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs.
Keiser P; Nassar N; Kvanli MB; Turner D; Smith JW; Skiest D
J Acquir Immune Defic Syndr; 2001 May; 27(1):14-9. PubMed ID: 11404515
[TBL] [Abstract][Full Text] [Related]
16. Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.
Hill AM; Gebo K; Hemmett L; Löthgren M; Allegri G; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():169-81. PubMed ID: 21182350
[TBL] [Abstract][Full Text] [Related]
17. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda.
Marseille E; Kahn JG; Pitter C; Bunnell R; Epalatai W; Jawe E; Were W; Mermin J
Appl Health Econ Health Policy; 2009; 7(4):229-43. PubMed ID: 19905037
[TBL] [Abstract][Full Text] [Related]
18. A comparative analysis of outpatient costs in HIV treatment programs.
Sarti FM; Nishijima M; Campino AC; Cyrillo DC
Rev Assoc Med Bras (1992); 2012; 58(5):561-7. PubMed ID: 23090227
[TBL] [Abstract][Full Text] [Related]
19. Costs of medical services for patients with HIV/AIDS in Khon Kaen, Thailand.
Kitajima T; Kobayashi Y; Chaipah W; Sato H; Chadbunchachai W; Thuennadee R
AIDS; 2003 Nov; 17(16):2375-81. PubMed ID: 14571190
[TBL] [Abstract][Full Text] [Related]
20. Costs of care provided in a university hospital for children exposed to or infected with the HIV/AIDS.
Marques HH; Couttolenc BF; Latorre Mdo R; Aquino MZ; Aveiro MI; Pluciennik AM
Cad Saude Publica; 2007; 23 Suppl 3():S402-13. PubMed ID: 17992346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
